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1Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK; 2Department of Clinical Biochemistry, Newcastle upon
Tyne Hospitals NHS Foundation Trust, UKAtherosclerosis has been described as a liver disease of the Apolipoprotein B (apoB)
heart [1]. The liver is the central regulatory organ of lipid path-
ways but since dyslipidaemias are major contributors to cardio-
vascular disease and type 2 diabetes rather than liver disease,
research in this area has not been a major focus for hepatologists.
Virus–host interaction is a continuous co-evolutionary process
[2] involving the host immune system and viral escape mecha-
nisms [3]. One of the strategies HCV has adopted to escape
immune clearance and establish persistent infection is to make
use of hepatic lipid pathways. This review aims to:
 update the hepatologist on lipid metabolism
 review the evidence that HCV exploits hepatic lipid pathways
to its advantage
 discuss approaches to targeting host lipid pathways as adjunc-
tive therapy.
 2011 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.The hepatic lipid pathway
Lipids act as energy sources for cells. Mammals have evolved a
sophisticated mechanism to enable hydrophobic fat to be made
soluble in the form of lipoproteins for delivery to peripheral tis-
sues. The role of hepatically-derived very-low-density lipoprotein
(VLDL) is thus to deliver energy, in the form of triglyceride (TG) to
cells requiring energy (skeletal muscle) or to cells that store
energy (adipose tissue). Lipoproteins can be characterised by
their densities related to their core lipid (TG and cholesteryl
ester) composition; the ﬁve main classes according to their den-
sity are chylomicrons (CM), VLDL, intermediate-density lipopro-
teins (IDL), low-density lipoprotein (LDL), and high-density
lipoproteins (HDL). Lipoproteins can also be characterised by
the major apolipoproteins present on their surfaces, some of
which are structural (apolipoproteins B and AI), whilst others
exchange between different lipoprotein particles (apolipopro-
teins AII, C, and E).Journal of Hepatology 20
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E-mail address: m.bassendine@ncl.ac.uk (M.F. Bassendine).Apolipoprotein B (apoB) exists as two distinct forms, apoB100
and apoB48 (the amino-terminal 48% of apoB100).
ApoB100 is the full length protein produced by the liver and
contains the low-density lipoprotein receptor (LDL-R)-binding
domain. ApoB100 is essential for VLDL assembly in hepatocytes
and is the structural lipoprotein present in VLDLs, IDL (also called
VLDL remnants), and LDL. The number of secreted VLDL is regu-
lated primarily by multiple degradative pathways for apoB
within the cell which are, in turn, regulated by metabolic factors
and pathways [4].
ApoB48, which lacks the LDL receptor-binding domain, is pri-
marily synthesized by the postnatal small intestine and is essen-
tial for chylomicron assembly in enterocytes. Hence apoB48 is the
intestinally-derived isoform of apoB100 on CM which transport
dietary lipids [5].Apolipoprotein E (apoE)
Apolipoprotein E (apoE) is a multifunctional protein that is syn-
thesized by the liver and several peripheral tissues and cell
types, including macrophages [6]. Insight into its multiple roles
in lipid and energy metabolism has been provided by the trans-
genic ApoE (/) mouse model [7]. ApoE is a critical ligand for
the receptor mediated removal of TG-rich lipoprotein (TRL) rem-
nants (VLDL and CM remnants) by the liver. ApoE not only acts
as a high afﬁnity ligand for multiple members of the LDL recep-
tor family including the LDL-R, the LDL receptor-related protein
(LRP), and the VLDL receptor but also binds to heparan sulphate
proteoglycans (HSPG), which act as hepatic receptors for TRL
remnant clearance. In addition, apoE participates in the biogen-
esis of discoidal HDL particles which are then converted to the
spherical form, by the action of lecithin:cholesterol acyltransfer-
ase (LCAT) allowing the recognition of HDL by the scavenger
receptor-B1 (SR-B1) [8]. ApoE also has an immune function
and mediates the presentation of serum-borne lipid antigens
[9].
Human apoE has three common isoforms (apoE2, apoE3, and
apoE4) which differ only by a single amino acid at two residues.
These differences affect structural and biophysical properties of
apoE resulting in different effects on lipid homeostasis. For exam-
ple apoE2 binds LDL-R with reduced afﬁnity [10] whilst apoE4
preferentially associates with VLDL.11 vol. 55 j 1428–1440
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Fig. 1. Pictorial representation of the transfer of exchangeable apolipopro-
teins (ApoCs, apoAII, § and apoE) between apoB-containing lipoprotein
particles (very-low density lipoprotein [VLDL], intermediate density lipopro-
tein [IDL], low density lipoprotein [LDL], and chlymicrons [CM]) and apoAI-
containing high-density lipoprotein [HDL] particles in the circulation. For
example in the fed state apoCIII preferentially redistributes to VLDL and CM.
Similarly HDL serves as a plasma reservoir of apoAII that transfers to TRLs in
much the same way as apoCs [20]. Discoidal HDL particles are converted to the
spherical form by the action of lecithin:cholesterol acyltransferase (LCAT) [8].
[Adapted from Ooi et al. [18]].
Table 1. Distribution of major apolipoproteins among the lipoprotein particle
family.
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JOURNAL OF HEPATOLOGYApolipoprotein Cs (apoCs)
The apoCs are a family of small exchangeable lipoproteins
(Table 1) which are important for the regulation of lipolysis. ApoCI
is a basic apolipoprotein that is mainly secreted by the liver as a
component of VLDLs. It can dissociate from the VLDL surface to
rapidly associate with HDLs and promote discoidal particle mor-
phology [11]. ApoC-I has multiple regulatory actions in plasma
TRL metabolism including inhibiting the binding and/or uptake
of VLDL by LDL-R and LRP. This is believed to be due to the ability
of apoC-I to displace signiﬁcant amounts of apoE fromTRL, or alter-
natively to mask or alter the conformation of apoE on these parti-
cles [12]. ApoCI also functions as an activator of LCAT and an
inhibitor of plasma cholesteryl ester transfer protein (CETP) [13].
Apolipoprotein CII (apoCII) is a necessary activator for lipopro-
tein lipase [14].
ApoCIII is synthesised by the liver and, in the fasting state, is
mainly associated with high-density lipoprotein (HDL) whereas
in the fed state, or in hyperlipidaemic individuals, it preferentially
redistributes to VLDL and CM (Fig. 1). ApoCIII is an important reg-
ulator of lipoprotein metabolism [15]; it impairs the lipolysis of
TRLs by inhibiting lipoprotein lipase and the hepatic uptake of
TRLs by remnant receptors. VLDL particles rich in apoCIII have a
reduced clearance rate whereas those rich in apoE rapidly clear
from the circulation [16,17]. It has also been shown that apoCIII
stimulates VLDL synthesis [18]. Hence total plasma apoCIII con-
centrations causally correlate with plasma TG concentrations.
Apolipoprotein As (ApoAs)
ApoAI is the principal apolipoprotein in HDL and has the ability
to interact with the SR-B1 hepatic receptor as well as activate
LCAT [19]. ApoAII is also associated with HDL where it is the sec-
ond most abundant protein (Table 1). ApoAII exchanges from HDL
to VLDL resulting in VLDL that is a poorer substrate for lipolytic
activity (Fig. 1). It is thus a regulator of VLDL metabolism and
apoAII levels in humans are associated with plasma concentra-
tions of TGs [20].
High-density lipoproteins (HDLs)
HDLs are small, dense, particles [density range of 1.063–
1.210 g/ml], some of which carry only ApoAI, whereas others con-Journal of Hepatology 2011tain both ApoAI and ApoAII. Other apolipoprotein species found
in HDL particles include ApoAIV, Apo C (CI, CII, and CIII), and
Apo E. The physical heterogeneity of HDLs is associated with mul-
tiple functions that involve both the protein and the lipid compo-
nents of these particles [19]. A major role of HDL is in the reverse
cholesterol transport process where cholesterol in peripheral tis-
sues is transported to the liver for reuse or bile acid synthesis. In
addition, recent data indicate that HDL participates in a mecha-
nism of intercellular communication involving the transport
and delivery of microRNAs [21].
VLDL assembly and secretion
VLDL particles secreted from the liver vary in size and composi-
tion and can be classiﬁed not only by their density
(0.94–1.06 g/ml), but also by their diameter (20–75 nm), and
ﬂotation rate [Svedberg ﬂotation rate (Sf) 20–400]. VLDL can be
separated into two main classes: large, buoyant VLDL1 particles
(Sf 60–400) which contain more TG and smaller denser VLDL2
particles (Sf 20–60).
Each VLDL contains a single non-exchangeable apoB100 mol-
ecule, which serves as its scaffolding, and exchangeable apolipo-
proteins including apoE and apoCs. The processes involved in the
assembly and secretion of VLDL have been studied extensively
in vitro and in vivo for the past two to three decades [5,22]. VLDL
assembly occurs via a two-step mechanism (Fig. 2), involving the
formation of apoB-containing VLDL precursor particles in the
lumen of the endoplasmic reticulum (ER), a step which requires
microsomal triglyceride-transfer protein (MTP) (reviewed in
[23]). This initial lipidation of apoB prevents proteosome-
mediated degradation. The VLDL precursor particles are then
loaded with neutral lipids by lipid droplets (LDs) [24,25] to form
TG rich VLDL1. It is thought that interplay between the length ofvol. 55 j 1428–1440 1429
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Fig. 2. Schematic representation of the two-stage VLDL assembly in hepatocytes. ApoB is translocated to the lumen of the ER and lipidated by microsomal triglyceride
transfer protein [MTP] to form pre-VLDL. Pre-VLDL is further lipidated to form VLDL2 or misfolded apoB can be degraded in the cell. VLDL2 is transferred to the Golgi and is
either secreted or further lipidated with a major load of triglyceride (TG) from the lipid droplet to form VLDL1. [Adapted from Olofsson et al. [166]].
ReviewapoB polypeptide and palmitoylation of apoB regulates TG-rich
lipoprotein assembly and secretion. In addition, apoE appears to
play a role in the formation of fully lipidated VLDL, whilst apoCIII
plays an intracellular role in stimulating VLDL assembly and
secretion.
Both the hepatic production rate and the circulating number
of VLDL1 particles are signiﬁcantly and strongly related to
HOMA-estimated insulin resistance (IR) in normoglycaemic
adults [26,27]. Disease phenotypes (e.g., type II diabetes, obesity)
also dramatically alter the total numbers and size of LDs, the
dynamic cellular structures involved in lipid homeostasis [25].
In contrast, the production rate and number of VLDL2 are not sig-
niﬁcantly related to insulin resistance.
Chylomicrons
Dietary fat is absorbed by the enterocyte, where a unique assem-
bly process similar to that of VLDL produces a ‘‘package’’ of lipid
and cholesterol with phospholipids and apoB-48 to form a chylo-
micron that is stable in the aqueous environment of the blood-
stream. Chylomicrons are the largest lipoproteins; CM access
the circulation via the thoracic duct where they are converted
to remnants by the TG hydrolysing action of lipoprotein lipase,
with apoCII acting as a co-factor and activator. The resultant
relatively TG-depleted, cholesterol-enriched CM remnant particle
is then cleared by the liver via an apoE dependent receptor-
mediated process. Thus, chylomicrons facilitate delivery of
dietary lipid and cholesterol to the liver [28].1430 Journal of Hepatology 2011Intravascular re-modelling of lipoproteins and removal of
lipid
Intravascular re-modelling of lipoproteins
Re-modelling entails the exchange of core and surface lipids and
apolipoproteins, mediated largely by the action of plasma lipid
transfer enzymes [lipoprotein lipase, hepatic lipase (HL), lipid
transfer proteins (CETP and phospholipid transfer protein (PLTP))
and LCAT].
Lipoprotein lipase (LPL) is the enzyme responsible for the
hydrolysis of core TG in VLDL and CM, producing IDL and chylo-
micron remnants, respectively. LPL is made in tissue parenchy-
mal cells and then translocated to functional binding sites at the
luminal surface of endothelial cells. LPL is anchored by ion
interaction with heparin sulphate proteoglycans (HSPG) and/or
glycosyl phosphatidylinositol. Once TRLs are bound to this plat-
form, LPL mediates TG hydrolysis, causing the release of fatty
acids that are then taken up by receptors located on the plasma
membrane of cells. Within these cells, the fatty acids are re-
esteriﬁed and used for storage in adipocytes or for energy pro-
duction in muscle. LPL requires a speciﬁc co-factor, apoCII, to be
fully active [14,29]. The enzymatic activity of LPL is regulated in
a complex manner in response to energy requirements and hor-
monal changes. For example insulin not only increases the level
of LPL mRNA in mature adipocytes but also regulates LPL
activity through post-transcriptional and post-translational
mechanisms. Conversely, interferon (IFN) decreases LPL activityvol. 55 j 1428–1440
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Fig. 3. Schematic representation of the life cycle of apoB-containing lipoprotein particles. Triglyceride-rich lipoproteins (VLDL1 and chylomicron (CM)) remnants
undergo rapid apoE-mediated clearance from the plasma (see Fig. 4). The lipolytic cascade produces low-density lipoprotein (LDL) particles largely from VLDL2 catabolism.
Statins have the largest LDL-cholesterol lowering effect among current licensed drugs by inhibiting the rate-limiting step in hepatic cholesterol synthesis, 3-hydroxy-3-
methylglutaryl CoA reductase (HMG-CoA).
JOURNAL OF HEPATOLOGYresulting in an increase in plasma TG [30–33]. Hepatic lipase
plays a major role in lipoprotein metabolism as a lipolytic
enzyme that hydrolyses TG and phospholipids in VLDL2, IDL,
CM remnants, and HDL [34].
CETP primarily transfers TG from VLDL in exchange for
cholesteryl esters from other lipoproteins, especially HDL [35].
Low-density lipoprotein is thus not directly secreted from
hepatocytes but is produced by VLDL catabolism. The lipolytic
cascade produces LDL particles which are depleted of TG and
enriched with cholesterol. During lipolysis of TRLs, apolipopro-
teins in their surface phospholipid coats are released and recycled
into HDL in serum. HDL particles are also secreted de novo from
hepatocytes.
Clearance of TRLs
The size of VLDL is a critical determinant in deciding the fate of
the particles in the circulation [36]. Thus, most of the large
TG-rich VLDL1 are cleared directly from the plasma [37] and less
than 20% of VLDL1 undergoes lipolysis all the way to LDL [38]
(Fig. 3).
Once TG-rich lipoproteins (VLDL1 and CM) are hydrolysed by
LPL, the resultant apoE-enriched TG-rich lipoprotein remnant
particles are removed in the liver by the concerted action of a
number of receptors [39,40]. Hepatic lipase on the basolateralJournal of Hepatology 2011surface of hepatocytes not only functions as a lipase but also
serves as a bridge/ligand that facilitates lipoprotein uptake. The
lipase-lipoprotein complex can then undergo internalisation, a
process that is independent of lipolysis and can be mediated by
HSPG, LDL-R, and LRP (Fig. 4), as well as SR-B1 (reviewed in
[40,41]). Syndecan1 is a HSPG that is essential for the binding
and clearance of TG-rich remnant lipoproteins [42,43]. SR-B1
might function as an initial recognition site for CM remnants with
subsequent internalisation by additional receptors such as LDL-R
[44]. Thus SRB1 not only promotes cellular uptake of cholesteryl
esters from HDL but also binds and facilitates the catabolism of
VLDL and CM [40,45]. Recent data conﬁrm complexity in the
interactions of lipoproteins with SR-B1 [46].
The ligand for these receptors is likely to be apoE since apoB
appears not to be in a receptor competent conformation on large
triglyceride-rich VLDL1. ApoCIII strongly inhibits hepatic uptake
of VLDL and IDL overriding the opposite inﬂuence of apoE when
both are present [17].HCV co-opts the hepatic lipid pathway
HCV infection is a highly dynamic process with a viral half life in
plasma of less than 3 h and production/clearance of an estimated
1012 virions per day in an infected individual [47]. Currently, it isvol. 55 j 1428–1440 1431
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Fig. 4. Hepatic TRL remnant clearance involves sequestration of the particles
through the fenestrae in the endothelium into the space of Disse. Two
endocytic receptors, the syndecan-1 heparan sulfate proteoglycan (HSPG) and the
LDL receptor, plus one docking receptor, SR-BI, signiﬁcantly contribute to normal
hepatic remnant catabolism [40], all of which have been implicated as cellular
receptors for HCV (red box). Hepatic lipase (HL) and apoE, secreted by the
hepatocytes (H), appear to bind to the HSPG and be available to enrich the remnant
lipoproteins and facilitate their uptake. [Adapted from Van Eck et al. [167]].
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Fig. 5. The buoyant density of HCV particles in human plasma is heteroge-
nous. High density HCV is associated with immunoglobulins, whilst low density
infectious HCV-lipo-viral particles (LVP) contain at least HCV RNA, HCV core
protein, TG and VLDL components apoB and apoE. HCV is able to transfer onto
TRLs in a manner similar to exchangeable lipoproteins [77]. Antibodies to apoCI
are able to neutralise >75% of infectious particles in vitro [87]. It is not known
whether immunoglobulin-loaded HCV can be exchanged.
Reviewbelieved that HCV co-opts the VLDL assembly, maturation, degra-
dation, and secretory machinery of the cell [48,49] and that the
production of infectious HCV virions coincides with the pathway
for producing VLDL/TRLs (reviewed in [50]. This virus–host inter-
action impacts on host lipid metabolism in ways which may be
HCV genotype (G) speciﬁc, such as induction of hepatic steatosis
and hypobetalipoproteinaemia, both of which are more frequent
and severe in HCV G3 infection [51,52].
The in vitro study of HCV replication has beneﬁtted from the
use of the replicon system and, more recently from the infection
competent HCV cell culture (HCVcc) system (reviewed in [53]).
However, the hepatoma cell lines used secrete relatively dense
lipid-poor apoB-containing particles, unlike the buoyant VLDL
particles secreted in vivo by the human liver [54]. The density
proﬁle of HCVcc particles shows an HCV RNA distribution from
1.0 to 1.18 g/ml with no infectivity at densities >1.12 g/ml [55].
It appears that HCV has evolved a mechanism of replication in
which lipid droplets, the intracellular storage sites for TG and
cholesteryl esters, are used to produce infectious virus. Associa-
tion of replication complexes with LDs occurs in a core and
NS5A-dependent manner [56–58], (reviewed in [59]). Recently,
it has been shown that the triglyceride-synthesizing enzyme
diacylglycerol acyltransferase-1 (DGAT1), an enzyme involved
in lipid droplet biogenesis, is another key host factor for HCV
infectious particle production [60].
Although apoB is essential for production of infectious virus
[61], HCV infectivity is closely related to the level of apoE present
in HCVcc particles [62] and biochemical analysis shows that
these particles have 290 ± 41 apoE molecules per viral RNA
[63]. Knockdown of apoE by a speciﬁc siRNA results in reductions
in infectious HCV [64] and an interaction between apoE and NS5A
is required for assembly of infectious HCV particles [65,66].1432 Journal of Hepatology 2011Virion associated cholesterol contributes to the interaction
between HCV particles and apoE [67]. Production of HCVcc from
serum free culture has shown that these viral particles have a
lower level of associated apoE and that lipids conjugated with
HCV affect infection and neutralization [68]. Recently, it has also
been shown that speciﬁc siRNA-mediated downregulation of
apoAI leads to a reduction of HCV RNA and viral particles
in vitro [69].
Infectious HCV particles can also be produced in primary
hepatocytes (HCVpc) [70]. Compared with HCVcc, HCVpc had
lower average buoyant density and higher speciﬁc infectivity,
similar to the characteristics of virus particles associated with
VLDL that are produced during in vivo infection.
The infectivity of hepatitis C viral particles is thus inversely
related to their density and low density particles have been
termed lipo-viral particles (LVP). LVPs in vivo are TG-rich and
contain at least viral RNA, HCV core protein, and the VLDL com-
ponents apoB and apoE [71–73]. It has long been recognised that
HCV in serum has a wide range of buoyant densities due to this
association with lipoproteins and immunoglobulins [74,75]. The
contribution of LVP to total HCV viral load varies widely in a
cohort of fasting chronic HCV G1 patients and correlates not only
with TG:HDL ratio and HOMA-IR but also with non-response to
anti-viral therapy [76]. The buoyant density of HCV particles in
human plasma is not only heterogeneous, but also dynamic and
dependent on TRL in circulation [77]. Very-low-density HCV
(density <1.025 g/ml) associated with TRLs (VLDL1, IDL, CM, and
CM remnants) rise 26-fold after a fatty meal and are rapidly
cleared from the circulation, rather than entering the lipolytic
cascade, suggesting removal via the hepatic TRL receptors [77].
These post-prandial LVP are associated with both apoB100 and
apoB48 TRLs [77], conﬁrming a previous study [72]. The markedvol. 55 j 1428–1440
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JOURNAL OF HEPATOLOGYincrease in these putative infectious LVP after a fatty meal
appears to be due not only to de novo production from infected
hepatocytes but also to intravascular transfer onto TRLs in a man-
ner similar to exchangeable lipoproteins (Fig. 5). These studies in
patients with chronic HCV suggest that HCV has not only
co-opted the VLDL assembly, maturation, degradation, and secre-
tory machinery of the hepatocyte but also utilises the intravascu-
lar remodelling of lipoproteins and the rapid removal of TRL
remnants by the liver to its advantage (Fig. 6).
HCV entry
The current model for HCV entry involves the initial docking of
the virus onto the cell surface through interactions of LVP with
cell surface HSPG and lipoprotein receptors (e.g. LDL-R, SR-B1)
which lead to conformational change(s) in the viral particle
allowing the engagement of other hepatocyte membrane co-
receptors (CD81, Claudin 1 (CLDN1) and Occludin (OCLN)
(reviewed in [78–80]). HCVcc infectivity is increased 18-fold in
Huh-7 cells over-expressing SR-B1 [81] and SR-BI appears to be
an essential HCV entry factor [82]. Thus, cellular receptors
involved in the uptake of VLDL and CM remnants in vivo (HSPG,
SR-B1 and LDL-R; Fig. 4) are also implicated as receptors for infec-
tious HCVcc particles. Blocking experiments show that VLDL itself
or anti-apoE antibody can block HCV LVP entry [83]. ApoE iso-
forms have been found to inﬂuence infectivity with the sugges-
tion that the apoE2 isoform, which has low afﬁnity for LDL-R,
being associated with poor infectivity both in vitro [84] andJournal of Hepatology 2011in vivo [85]. It is likely that the balance of apoE and apoCs on LVPs
is involved in cell entry. ApoCI appears to be involved in infectiv-
ity; it is recruited by HCV glycoproteins on the viral surface and
promotes fusion of HCV particles with membranes [86]. ApoCI
also enhances HCVpp infectivity [87].The lipid pathway as a therapeutic target in chronic HCV
The current standard of care (SoC) for the treatment of hepatitis C
virus (HCV) infection is a combination of pegylated IFN and riba-
virin (Peg-IFN/RBV) [88], but this cures around 50% (sustained
virological response (SVR) = undetectable HCV RNA for greater
than 24 weeks after cessation of therapy). There is hence an
urgent need for better treatment and a huge array of potential
targets for the development of new classes of HCV therapies
[89], which has focused initially on ‘‘direct-acting anti-virals’’
(DAAs) [90]. These represent a major step forward but the
emergence of drug-resistant virus in patients with viral break-
through on treatment needs to be addressed [91,92].
HCV–lipid interactions represent attractive targets for
indirect-acting antiviral (IDAA) development because it is more
difﬁcult for the virus to develop escape mutations against
therapeutics that target host cell factors. In addition, as dyslipida-
emia in the metabolic syndrome is central to cardiovascular
disease, a number of therapeutic interventions are already in
use or under development for this indication [93]. An under-
standing of how HCV genotypes interact with lipid pathways isvol. 55 j 1428–1440 1433
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thus central to the use of these treatments ‘‘off-label’’ for a
condition not approved in the marketing authorization [94].Diet and lifestyle modiﬁcations
Obesity may be associated with decreased efﬁcacy of current
SOC [95]. Modest weight loss optimally decreases plasma TG
and LDL-cholesterol via reduction in hepatic apoB secretion
[96]. One small unconﬁrmed study in patients with chronic hep-
atitis C (CHC) has reported an association of a mean weight loss
of only 5.9 kg with a reduction in steatosis and abnormal liver
enzymes and an improvement in ﬁbrosis, despite the persistence
of HCV [97]. Conversely, high visceral adiposity is associated
with both steatosis and high viral load in G1-CHC [98]. Hence,
management of dyslipidaemia with diet and exercise may pro-
vide an adjunct treatment strategy for obese patients with
CHC [99].
Omega-3-fatty acids
Fish oils are a rich source of omega-3-fatty acids, eicosapentaenoic
acid and docosahexanoic acid. Fish oils diminish hepatic secretion
of VLDL-apoB [96]. Several polyunsaturated fatty acids (PUFA)
including eicosapentaenoic acid and docosahexanoic acid
dramatically inhibit HCV replication in vitro using the HCV RNA
replicon system [100]. When combined with IFN-alpha, PUFAs
have a strong synergistic anti-HCVeffect in vitro [101], but no stud-
ies have evaluated whether omega-3-fatty acids can provide syn-
ergistic antiviral effects when given as food supplements during
IFN-based anti-HCV therapy in patients.
Pharmacological interventions
Targeting LVP assembly, maturation and secretion
Lipid lowering drugs differ strongly with respect to the types of
lipids or lipoproteins that they predominantly affect. The major
classes of drugs that lower cholesterol are statins and cholesterol
absorption inhibitors, whilst those that lower triglycerides are
ﬁbrates and omega-3 fatty acids. Nicotinic acid has a hybrid posi-
tion in that it decreases both TG and cholesterol. As a rule, TG
lowering drugs increase HDL-cholesterol and nicotinic acid is
the strongest HDL raising drug in current clinical use.
Statins
Statins inhibit the de novo synthesis of cholesterol in the liver by
blocking mevalonate production via inhibition of 3-hydroxy-
3-methylglutaryl CoA reductase (HMG CoA reductase) (Fig. 3)
and have other pleiotropic effects. Initial in vitro studies in geno-
mic and sub-genomic HCV RNA replicons showed that lovastatin
markedly reduced HCV RNA levels [102]. This effect was shown
to be mediated by inhibiting geranylgeranylation of a host pro-
tein FBL2 required for HCV replication [100]. In vitro, different
statins show a hierarchy of inhibition of HCV replication, with
pravastatin being devoid of an anti-viral effect [103,104]. The
sensitivity of HCV to an individual statin may also vary [105].
In combination with IFN-a, both ﬂuvastatin and pitavastatin
show strong synergistic activity and enhance the anti-HCV effect
of IFN-a [103,106]. Statins may be a useful adjunctive therapy
with HCV polymerase or protease inhibitors as an additive antivi-
ral effect has been reported with mevastatin or simvastatin1434 Journal of Hepatology 2011in vitro in short-term (3 days) antiviral assays [104]. However,
the potential for clinically relevant drug–drug interactions
between statins and DAAs via CYP450-dependent metabolism
[107] could present a problem, similar to that encountered in
the treatment of HIV infection with ‘‘ritonovir-boosted’’ protease
inhibitors [108].
The clinical data with statins are limited, but indicate that sta-
tin monotherapy has little anti-viral effect [109–113], although
combination therapy is more promising and adequately powered
randomised controlled trials are needed.
The disappointing and sometimes contradictory results using
statin monotherapy in vivo may be partially explained by dose
effects. With conventional doses, the serum concentration of
the statin may be 10-fold lower than that found be effective in
the HCV replicon systems. Also, besides their effect on HCV rep-
lication, statins cause up-regulation of LDL-R and hence may
enhance HCV infectivity of hepatocytes, abrogating or even
reversing any beneﬁcial effects of monotherapy in vivo.
Combining a statin with Peg-IFN/RBV appears more promising
[114] (Table 2). In HCV/HIVco-infection, combination of ﬂuvasta-
tin with Peg-IFN/RBV signiﬁcantly improved the rapid virological
response (RVR) rate [115]. In patients with HCV-G1 infection
treated in the IDEAL study [116], multivariate logistic regression
analysis showed that pre-emptive statin use was independently
associated with SVR. This has been conﬁrmed by a large retro-
spective study utilising the USA Veterans Affairs administrative
database where statin use was associated with an improved
SVR among both diabetic patients and nondiabetic patients
receiving combination antiviral therapy [117].Peroxisome proliferator-activated receptor (PPAR) agonists
PPARs belong to the steroid/thyroid/retinoid receptor superfam-
ily and are nuclear lipid-activable receptors that control a variety
of genes in several pathways of lipid metabolism [118]. In addi-
tion to being activated by fatty acids, they respond to ﬁbric acid
derivatives and thiazolidinediones.PPARa agonists
Fibrates decrease hepatic VLDL secretion and enhance clearance,
hence reducing plasma TG by 30–50% [119]. They are particu-
larly beneﬁcial in overweight people with high plasma TG levels
and low levels of HDL cholesterol (HDL-C). Lower TGs associate
with higher rates of SVR in CHC-G1 [120], but there is conﬂict-
ing data on the use of ﬁbrates in HCV. One in vitro study show-
ing binding of HCV core protein to apoAII reported that
fenoﬁbrate treatment resulted in a parallel increase in apoAII
and core protein secretion [121]. Another found that use of a
PPAR-a antagonist resulted in disruption of HCV replication
complexes [122]. However, a recent study in a sub-genomic rep-
licon model for HCV-induced steatosis shows that fenoﬁbrate
reduced ER stress [123] whilst a pilot study in patients has sug-
gested that bezaﬁbrate may be useful in combination with Peg-
IFN/RBV [124].PPAR-c agonists
Both pioglitazone and rosiglitazone are effective in reducing
liver fat content by 30–50% and sensitizing the liver to insulin
but they have different effects on serum lipids [125]. Pioglitaz-
one has a beneﬁcial effect on fasting and post-prandial plasma
triglycerides and reduces hepatic de novo lipogenesisvol. 55 j 1428–1440
Table 2. Examples of studies evaluating lipid-modulating therapies in vivo and their effect on HCV.
Lipid-modulating drug Study design Effect on HCV [Reference]
Fluvastatin 80 mg daily 
+ SoC
Pilot: (n = 44 HIV/HCV genotype 1 
co-infected patients)
Improved RVR (p = 0.02) and 
trend to improved SVR (p = 0.08)
Milazzo, L et al., 2010 [115]
Use of any statin + SoC Retrospective analysis of IDEAL 
study [116] (n = 66 on statin)
Improved SVR
(OR = 2.0, p = 0.02) 
Harrison, SA et al., 2010 [156]
Use of any statin + SoC Retrospective analysis of VA data-
base (n = 1704 diabetic patients
and 6589 nondiabetic patients) 
Improved SVR among both 
diabetic patients (OR, 1.52; p = 
0.0124) and nondiabetic patients
Rao, GA and Pandya, PK, 2011 [117]
for 8 weeks
Pilot study (n = 15) Fall in viral load Fujita, N et al.,  2006 [124]
Pioglitazone Randomised controlled (n = 97 HCV 
genotype 4 patients with HOMA >2)
Improved RVR (p = 0.006)  and 
SVR  (p = 0.04)
Khattab, M et al.,  2010 [128]
Niacin (and other dietary 
factors) + SoC 
Prospective study of dietary habits
(n = 1084)
Improved SVR Loguercio, C et al.,  2008 [135]
Silibinin Pilot study (n = 16 for 7 days IV and 
n = 20 for 14 days IV)
Dose dependent suppression of 
HCV viraemia
Ferenci, P et al.,  2008 [138] 
Therapeutic silencing of 
microRNA-122 (SPC3649)
Study in primates Long lasting suppression of HCV 
viraemia
Lanford, RE et al.,  2010 [149]
SR-BI antagonist, 
(ITX 5061)
Phase 1 pilot studies (n ≥280 sub-
jects)
Inhibition of HCV entry Syder, AJ et al.,  2011 (in vitro data) [160]
phoresis + SoC
Pilot study (genotype 2a: n = 2, 
genotype 1b: n = 10 NR patients)
Improved SVR Ohara, T et al., 2011 [162]
Bezafibrate (400 mg/day) 
Double filtration plasma-
SoC, standard of care [168]: NR, non-responder; RVR, rapid virological response; SVR, sustained virological response.
JOURNAL OF HEPATOLOGY[126,127]. Pioglitazone has been used in chronic HCV with the
rationale that insulin resistance affects SVR. A study in treat-
ment naïve HCV genotype 4 patients with HOMA-IR >2 has
reported increased RVR, SVR and decreased IR in those receiving
triple combination therapy (pioglitazone/Peg-IFN/RBV) (Table 2)
[128]. The dose and schedule of use of pioglitazone may be
important [129], with the suggestion that sequential rather than
concomitant use is preferable [130]. In addition the response
may be affected by genotype-dependent HCV–host interactions
[131]. Further understanding of the effect of these compounds
on HCV–lipid interaction in addition to simple insulin sensitisat-
ion is required to inform trial design. Measurement of LVP [76]
in addition to total HCV viral load and HOMA-IR is likely to be
informative.
Niacin (Nicotinic acid)
Niacin is a water-soluble B vitamin (B3) which decreases plasma
triglycerides by 25%, increases HDL-C and reduces LDL choles-
terol modestly [132]. Its use has been hampered because it can
cause frequent ﬂushing of the skin, but addition of a prostaglan-
din receptor blocker, laropiprant, improves this side effect
[133,134]. In patients with CHC G1 there is a strong correlation
between fasting LVP and TG:HDL ratio [76] and a post-prandial
surge in TG-rich LVPs [77], suggesting that niacin may be
beneﬁcial as an adjunct to SoC. This is supported by a recent
cross-sectional and longitudinal analysis of HCV RNA viral loads
in chronic HCV patients with dyslipidaemia in which hypertrigly-
cerideamia was found to correlate with HCV titres and niacin
exposure was associated with signiﬁcantly lower viral titres
[113]. Another study has also reported signiﬁcant differences in
niacin intake between responders and non-responders to inter-
feron therapy [135]. Niacin warrants further evaluation, either
alone or in combination with a statin [136] as adjunctive therapy,Journal of Hepatology 2011particularly in patients with HCV genotype 1, body weightP
85 kg, and high baseline viral load who respond poorly to Peg-
IFN/RBV [137].
Silymarin
Silymarin, a mixture of ﬂavolignans extracted from the milk
thistle plant Silybum marianum, is widely used as a traditional
herbal remedy for self-treatment of chronic HCV. The main com-
ponent of silymarin is silibinin which has been shown to inhibit
HCV infection both in vitro and in vivo [138].The mechanism of
action of silymarin is complex but it includes decreasing infec-
tious virion production by blocking MTP-dependent apoB secre-
tion [139]. The plant ﬂavanoid taxifolin, also present in milk
thistle, has likewise been shown to decrease hepatic lipid synthe-
sis by decreasing apoB and increasing apoAI secretion [140]. As
silymarin-derived compounds may inﬂuence HCV disease course
in some patients [141], studies where standardized compounds
are dosed to identify speciﬁc clinical endpoints are urgently
needed. Initial case reports using silibinin to prevent graft rein-
fection after orthotopic liver transplantation are encouraging
[142,143].
ApoB antisense
An antisense inhibitor of apoB synthesis, mipomersen, has
recently been shown to be effective and safe as an adjunctive
agent to lower LDL cholesterol concentrations in patients with
familial hypercholesterolaemia [144,145]. Mipomersen contains
an endonuclease resistant modiﬁed sequence of nucleotides com-
plementary to ApoB mRNA which binds to and inhibits the trans-
lation of the encoded sequence into the mature protein, reducing
the synthesis and secretion of the apolipoprotein B lipoproteins
VLDL and LDL [146]. As silencing ApoB mRNA in the HCVcc sys-
tem causes a 70% reduction in the secretion of both ApoB100vol. 55 j 1428–1440 1435
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and HCV [49,61,147], this novel drug may warrant evaluation in
chronic HCV infection.MicroRNA-122 inhibition
MicroRNAs (miRNAs) are small noncoding RNAs that regulate
gene expression at post-transcriptional level. Some miRNAs have
been associated with lipid metabolism; for example miR-122
inhibition in normal mice results in reduced plasma cholesterol
levels [148]. Recent work has shown that therapeutic silencing
ofmiRNA-122 in primates with CHC leads to long lasting suppres-
sion of HCV viraemia [149].Novel targets
3b-Hydroxysterol D24-reductase (DHCR24) inhibitors
DHCR24 is an enzyme in the cholesterol biosynthetic pathway,
converting desmosterol to cholesterol [150]. This enzyme is
induced by HCV infection in human hepatocytes in vitro and an
inhibitor of DHCR24 has recently been shown to have an anti-
viral effect in chimeric mice with HCV infection in their human-
ised liver [151].Diacylglycerol acyltransferase 1 (DGAT1) inhibitors
DGAT1 interacts with HCV core and is required for its trafﬁcking
to lipid droplets. Inhibition of DGAT1 activity or RNAi-mediated
knockdown of DGAT1 severely impairs infectious virion produc-
tion, implicating DGAT1 as a new target for antiviral therapy [60].Long chain acyl-CoA synthetase 3 (ACSL3) inhibitors
ACSL3 is required for incorporation of fatty acids into phospha-
tidylcholine, a reaction that is essential for VLDL assembly. It
has been shown that secretion of VLDL as well as HCV is inhib-
ited when expression of ACSL3 is reduced by RNA interference
[152]. This study identiﬁed ACSL3 as a new enzyme required
for VLDL assembly, conﬁrmed the link between VLDL assembly
and HCV production and suggested that ACSL3 is a new enzy-
matic target for limiting both VLDL secretion and HCV
infection.Polyunsaturated liposomes (PERLS)
Liposomes capable of ER-targeted drug delivery have been devel-
oped [153] and polyunsaturated ER-targeting liposomes have
been reported to decrease secretion and infectivity of HCVcc
[154]. PERLS may target multiple points in the lipid pathway,
not only lowering intracellular cholesterol and LD number but
also competing with lipoproteins for cell entry.Targeting intravascular re-modelling of LVP and clearance via TRL
receptors
The demonstration that HCV particles behave in a manner similar
to exchangeable lipoproteins and transfer onto TRLs [77] opens
up further potential targets once the pathophysiology of this pro-
cess is understood. Drugs that lower TG such as niacin or target
LD biogenesis may be more effective in vivo than interventions
aimed at lowering LDL via the cholesterol pathway such as stat-
ins. Indeed high LDL-cholesterol is associated with SVR in
patients receiving Peg-IFN/RBV [155,156] whilst high TG is asso-
ciated with both viral load and hepatic steatosis [120].1436 Journal of Hepatology 2011CETP inhibitors
Successful HCV infection of SCID/uPA mice transplanted with
human hepatocytes correlates with expression of markers of
human lipoprotein biosynthesis, human apoB and CETP,
suggesting that CETP may be involved in the infectious cycle of
HCV [157]. This raises the intriguing question of whether small-
molecule CETP inhibitors (dalcetrapib, torcetrapib, and anacetra-
pib) which have been or are being tested in phase 3 clinical
studies, may be of beneﬁt in chronic HCV [158].
HCV entry inhibitors
HCV entry inhibitors would limit the expansion of the infected
cell reservoir and complement other approaches to therapy. SR-BI
appears to be an essential HCV entry factor [82]. SR-B1 residues
involved in HCV recognition are not required for HDL binding
or SR-BI-mediated cholesterol efﬂux, suggesting that the devel-
opment of agents selectively inhibiting HCV infection, but with
no or low impact on the reverse cholesterol pathway, is a feasible
task [46,159]. Recently a small molecule SR-BI antagonist, ITX
5061, has been shown to have potent antiviral activity against
HCVpp and HCVcc [160]. This orally active agent is now being
evaluated in the clinic in chronic HCV patients and patients
undergoing liver transplantation.
Double ﬁltration plasmaphoresis (DFPP)
Heparin-induced extracorporeal low-density lipoprotein precipi-
tation (HELP) apheresis is an effective tool to eliminate apoB
containing lipoproteins from the circulation and has been found
to reduce HCV–RNA by 77% [161]. DFPP is a similar technique
which uses a plasma separator (ﬁrst ﬁlter) to separate plasma
and blood cells from blood and a plasma fractionator (second ﬁl-
ter) to eliminate high-molecular-weight substances. DFPP can
mechanically eliminate not only lipoproteins but also HCV from
the blood. It was approved in Japan in 2008 for the retreatment
of chronic HCV G1b patients with high viral loads but has sim-
ilar effects in chronic HCV G2 infection [162]. DFPP may be use-
ful in combination with IFN in some patients, especially those
with cryoglobulinaemia [163,164] but there are safety issues
as DFPP also decreases other plasma proteins including factor
XIII [165].
In summary, HCV–host interaction is a continuous co-evolu-
tionary process and phylogenetic analysis of 345 full-length
HCV genomic sequences suggests different evolutionary ages of
the major HCV genotypes [2]. It is now clear that the equilibrium
established between HCV and the host in chronic infection
involves not only the immune response but also lipid pathways,
some of which may be genotype-speciﬁc. Better understanding
of how HCV utilises these pathways in its life cycle will lead to
more options for therapy. These include not only lipid-modulat-
ing drugs already in use or in development for other indications
[e.g. statins, niacin, CETP inhibitors, apoB antisense, miRNA-122
inhibitors] but also entry inhibitors [e.g. SR-BI antagonists] and
novel targets [e.g. diacylglycerol acyltransferase 1 inhibitors, long
chain acyl-CoA synthetase 3 inhibitors].Conﬂict of interest
The authors declared that they do not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.vol. 55 j 1428–1440
JOURNAL OF HEPATOLOGYKey Points  
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HCV has evolved a mechanism of replication in 
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lipo-viral particles (LVP) are TG-
least viral RNA, HCV core protein and the VLDL 
components apoB and apoE.  
Understanding the complex interaction of HCV with 
lipid metabolism, which may be genotype 
dependent, will lead to a number of possible new 
indirect-acting antiviral (IDAA) treatment options. 
These include not only lipid-modulating drugs
already in use or in development for other 
indications but also LVP entry inhibitors and novel 
targets. 
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